Tenax Therapeutics, Inc. (NASDAQ:TENX) Receives $16.00 Consensus PT from Analysts

Tenax Therapeutics, Inc. (NASDAQ:TENX) has been assigned a consensus recommendation of “Buy” from the five brokerages that are covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $16.00.

A number of analysts have recently commented on TENX shares. William Blair started coverage on Tenax Therapeutics in a research report on Monday, September 30th. They set an “outperform” rating on the stock. Leerink Partnrs upgraded Tenax Therapeutics to a “strong-buy” rating in a research report on Thursday, October 24th. Leerink Partners started coverage on Tenax Therapeutics in a research report on Thursday, October 24th. They set an “outperform” rating and a $16.00 target price on the stock. Guggenheim started coverage on Tenax Therapeutics in a research report on Monday, October 14th. They set a “buy” rating and a $16.00 target price on the stock. Finally, StockNews.com started coverage on Tenax Therapeutics in a research report on Thursday, September 26th. They set a “sell” rating on the stock.

Hedge Funds Weigh In On Tenax Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in TENX. Stonepine Capital Management LLC purchased a new position in shares of Tenax Therapeutics during the third quarter worth about $173,000. Vestal Point Capital LP purchased a new stake in Tenax Therapeutics in the 3rd quarter valued at approximately $288,000. Finally, Sphera Funds Management LTD. purchased a new stake in Tenax Therapeutics in the 3rd quarter valued at approximately $101,000. Hedge funds and other institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Stock Performance

Tenax Therapeutics stock opened at $5.06 on Tuesday. Tenax Therapeutics has a 1-year low of $2.77 and a 1-year high of $33.44. The stock’s fifty day moving average is $4.13 and its two-hundred day moving average is $3.74.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.